Build your base

Alienum phaedrum torquatos nec eu, vis detraxit periculis ex, nihil expetendis in mei. Mei an pericula euripidis, hinc partem ei est.
Back to top

Angela James, PhD

New Horizon / Angela James, PhD
Angela James

Angela James, PhD

Vice President, Head of Clinical Pharmacology, MacroGenics Inc.


Dr. Angela James is the Vice-Chair of Women in Bio and an accomplished scientist with expertise in drug development which she is currently applying in her role as Vice President, Head of Clinical Pharmacology, at MacroGenics Inc., a company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Dr. James earned a B.A. in Biology from Rice University and a Ph.D. in Pharmaceutical Sciences with a research focus in Pharmacokinetic/Pharmacodynamic Modeling and Simulation from University of Maryland, Baltimore. She later received a M.S. in Pharmacometrics from University of Maryland, Baltimore. She is passionate about utilizing her scientific acumen and leadership abilities to bring novel therapeutics to patients who urgently need safe and effective drugs. Equally important is her role as a mentor for early career scientists and students of all ages.

As she gained experience as a Global Clinical Pharmacology Lead, her career trajectory led her to roles at Alcon/Novartis, Celgene and Astellas Pharma. As the Global Clinical Pharmacology Lead at Astellas Pharma, she designed and successfully lead the execution of the Clinical Pharmacology strategy, for the successful approval of XOSPATA® (gilteritinib) for the treatment of adult patients with relapsed or refractory AML with a FLT3 mutation. Prior to leaving Astella, Dr. James was a Global Development Project Leader and led cross-functional project teams to successfully execute on global strategies for the development of novel immuno-oncology agents including an innovative cancer vaccine.